Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

导出 OA

翻译打印收藏纠错

作者： François,Girardin ^[1] ; Oriol,Manuel ^[2] ; Catia,Marzolini ^[3] ; Thierry,Buclin ^[4]

作者单位： Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland. Electronic address: francois.girardin@chuv.ch. ^[1] Infectious Diseases Service and Transplantation Centre, Lausanne, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland. ^[2] Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland; Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom. ^[3] Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland. ^[4]

关键词 Antivirals COVID-19 Drug safety Drug-drug interactions Nirmatrelvir Pharmacokinetic boosters Ritonavir

主题词抗病毒药(Antiviral Agents);药物相互作用(Drug Interactions);人类(Humans);利托纳韦(Ritonavir)

DOI 10.1016/j.cmi.2022.03.030

PMID 35358684

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交